Free Trial
TSE:PMN

ProMIS Neurosciences (PMN) Stock Price, News & Analysis

ProMIS Neurosciences logo

About ProMIS Neurosciences Stock (TSE:PMN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
19,701 shs
Average Volume
3,327 shs
Market Capitalization
C$51.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Receive PMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

PMN Stock News Headlines

Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
ProMIS Neurosciences initiates Phase 1b trial in Alzheimer’s disease
ProMIS Neurosciences stock hits 52-week low at $0.91
ProMIS Neurosciences reports Q3 EPS 31c vs (19c) last year
See More Headlines

PMN Stock Analysis - Frequently Asked Questions

Shares of PMN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that ProMIS Neurosciences investors own include CRISPR Therapeutics (CRSP), Aurora Cannabis (ACB), Keurig Dr Pepper (KDP), Biocept (BIOC), Onconova Therapeutics (ONTX), Spectra7 Microsystems (SEV) and TherapeuticsMD (TXMD).

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
TSE:PMN
Previous Symbol
TSE:AMF
CIK
N/A
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-20,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$7,558.00
Price / Cash Flow
14.07
Book Value
C($0.72) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
C$51.48 million
Optionable
Not Optionable
Beta
1.19
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (TSE:PMN) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners